Next Article in Journal
Analysis of Expressed Sequence Tags from Chinese Bayberry Fruit (Myrica rubra Sieb. and Zucc.) at Different Ripening Stages and Their Association with Fruit Quality Development
Next Article in Special Issue
Gonadotropins Activate Oncogenic Pathways to Enhance Proliferation in Normal Mouse Ovarian Surface Epithelium
Previous Article in Journal
A Comparative Study of Selected Trace Element Content in Malay and Chinese Traditional Herbal Medicine (THM) Using an Inductively Coupled Plasma-Mass Spectrometer (ICP-MS)
Previous Article in Special Issue
Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening
Int. J. Mol. Sci. 2013, 14(2), 3094-3109; doi:10.3390/ijms14023094
Article

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

1,* , 1
, 1
, 1
, 2
, 2
, 1
, 1
 and 1
Received: 16 January 2013; in revised form: 25 January 2013 / Accepted: 28 January 2013 / Published: 1 February 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
View Full-Text   |   Download PDF [1782 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Approximately 25,000 ovarian cancers are diagnosed in the U.S. annually, and 75% are in the advanced stage and largely incurable. There is critical need for early detection tools and novel treatments. Proteasomal ubiquitin receptor ADRM1 is a protein that is encoded by the ADRM1 gene. Recently, we showed that among 20q13-amplified genes in ovarian cancer, ADRM1 overexpression was the most highly correlated with amplification and was significantly upregulated with respect to stage, recurrence, and metastasis. Its overexpression correlated significantly with shorter time to recurrence and overall survival. Array-CGH and microarray expression of ovarian cancer cell lines provided evidence consistent with primary tumor data that ADRM1 is a 20q13 amplification target. Herein, we confirm the ADRM1 amplicon in a second ovarian cancer cohort and define a minimally amplified region of 262 KB encompassing seven genes. Additionally, using RNAi knock-down of ADRM1 in naturally amplified cell line OAW42 and overexpression of ADRM1 via transfection in ES2, we show that (1) ADRM1 overexpression increases proliferation, migration, and growth in soft agar, and (2) knock-down of ADRM1 results in apoptosis. Proteomic analysis of cells with ADRM1 knock-down reveals dysregulation of proteins including CDK-activating kinase assembly factor MAT1. Taken together, the results indicate that amplified ADRM1 is involved in cell proliferation, migration and survival in ovarian cancer cells, supporting a role as an oncogene and novel therapeutic target for ovarian cancer.
Keywords: ADRM1; oncogene; ovarian cancer ADRM1; oncogene; ovarian cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Fejzo, M.S.; Anderson, L.; von Euw, E.M.; Kalous, O.; Avliyakulov, N.K.; Haykinson, M.J.; Konecny, G.E.; Finn, R.S.; Slamon, D.J. Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 3094-3109.

AMA Style

Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ. Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(2):3094-3109.

Chicago/Turabian Style

Fejzo, Marlena S.; Anderson, Lee; von Euw, Erika M.; Kalous, Ondrej; Avliyakulov, Nuraly K.; Haykinson, Michael J.; Konecny, Gottfried E.; Finn, Richard S.; Slamon, Dennis J. 2013. "Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer." Int. J. Mol. Sci. 14, no. 2: 3094-3109.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert